Author
Listed:
- Benjamin S. Freedman
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
University of Washington School of Medicine
Kidney Research Institute, University of Washington
Institute for Stem Cell and Regenerative Medicine, University of Washington)
- Craig R. Brooks
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine)
- Albert Q. Lam
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Harvard Stem Cell Institute, Harvard University)
- Hongxia Fu
(Boston Children’s Hospital, Center for Life Sciences, Harvard Medical School)
- Ryuji Morizane
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine)
- Vishesh Agrawal
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Brigham and Women’s Hospital, Harvard Medical School)
- Abdelaziz F. Saad
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine)
- Michelle K. Li
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Harvard University)
- Michael R. Hughes
(The Biomedical Research Centre, University of British Columbia)
- Ryan Vander Werff
(The Biomedical Research Centre, University of British Columbia)
- Derek T. Peters
(Harvard University
Brigham and Women’s Hospital, Harvard Medical School)
- Junjie Lu
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Brigham and Women’s Hospital, Harvard Medical School)
- Anna Baccei
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Brigham and Women’s Hospital, Harvard Medical School)
- Andrew M. Siedlecki
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine)
- M. Todd Valerius
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Harvard Stem Cell Institute, Harvard University)
- Kiran Musunuru
(Harvard University
Brigham and Women’s Hospital, Harvard Medical School)
- Kelly M. McNagny
(The Biomedical Research Centre, University of British Columbia)
- Theodore I. Steinman
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Beth Israel Deaconess Medical Center, Harvard Medical School)
- Jing Zhou
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Harvard Stem Cell Institute, Harvard University)
- Paul H. Lerou
(Harvard Stem Cell Institute, Harvard University
Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Brigham and Women’s Hospital, Harvard Medical School)
- Joseph V. Bonventre
(Brigham and Women’s Hospital, Harvard Medical School, Harvard Institutes of Medicine
Harvard Stem Cell Institute, Harvard University)
Abstract
Human-pluripotent-stem-cell-derived kidney cells (hPSC-KCs) have important potential for disease modelling and regeneration. Whether the hPSC-KCs can reconstitute tissue-specific phenotypes is currently unknown. Here we show that hPSC-KCs self-organize into kidney organoids that functionally recapitulate tissue-specific epithelial physiology, including disease phenotypes after genome editing. In three-dimensional cultures, epiblast-stage hPSCs form spheroids surrounding hollow, amniotic-like cavities. GSK3β inhibition differentiates spheroids into segmented, nephron-like kidney organoids containing cell populations with characteristics of proximal tubules, podocytes and endothelium. Tubules accumulate dextran and methotrexate transport cargoes, and express kidney injury molecule-1 after nephrotoxic chemical injury. CRISPR/Cas9 knockout of podocalyxin causes junctional organization defects in podocyte-like cells. Knockout of the polycystic kidney disease genes PKD1 or PKD2 induces cyst formation from kidney tubules. All of these functional phenotypes are distinct from effects in epiblast spheroids, indicating that they are tissue specific. Our findings establish a reproducible, versatile three-dimensional framework for human epithelial disease modelling and regenerative medicine applications.
Suggested Citation
Benjamin S. Freedman & Craig R. Brooks & Albert Q. Lam & Hongxia Fu & Ryuji Morizane & Vishesh Agrawal & Abdelaziz F. Saad & Michelle K. Li & Michael R. Hughes & Ryan Vander Werff & Derek T. Peters & , 2015.
"Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids,"
Nature Communications, Nature, vol. 6(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9715
DOI: 10.1038/ncomms9715
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Jessica M. Vanslambrouck & Sean B. Wilson & Ker Sin Tan & Ella Groenewegen & Rajeev Rudraraju & Jessica Neil & Kynan T. Lawlor & Sophia Mah & Michelle Scurr & Sara E. Howden & Kanta Subbarao & Melissa, 2022.
"Enhanced metanephric specification to functional proximal tubule enables toxicity screening and infectious disease modelling in kidney organoids,"
Nature Communications, Nature, vol. 13(1), pages 1-23, December.
- Sienna R. Li & Ramila E. Gulieva & Louisa Helms & Nelly M. Cruz & Thomas Vincent & Hongxia Fu & Jonathan Himmelfarb & Benjamin S. Freedman, 2022.
"Glucose absorption drives cystogenesis in a human organoid-on-chip model of polycystic kidney disease,"
Nature Communications, Nature, vol. 13(1), pages 1-12, December.
- Moritz Lassé & Jamal El Saghir & Celine C. Berthier & Sean Eddy & Matthew Fischer & Sandra D. Laufer & Dominik Kylies & Arvid Hutzfeldt & Léna Lydie Bonin & Bernhard Dumoulin & Rajasree Menon & Virgin, 2023.
"An integrated organoid omics map extends modeling potential of kidney disease,"
Nature Communications, Nature, vol. 14(1), pages 1-21, December.
- J. O. R. Hernandez & X. Wang & M. Vazquez-Segoviano & M. Lopez-Marfil & M. F. Sobral-Reyes & A. Moran-Horowich & M. Sundberg & D. O. Lopez-Cantu & C. K. Probst & G. U. Ruiz-Esparza & K. Giannikou & R., 2021.
"A tissue-bioengineering strategy for modeling rare human kidney diseases in vivo,"
Nature Communications, Nature, vol. 12(1), pages 1-16, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms9715. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.